Bonus Episode: Exploring the Clinical Benefits and Therapeutic Approaches for Managing Type 2 Diabetes

In this episode, the experts focus on incretin hormones, their clinical benefits, and therapeutic approaches, providing valuable insights into incretin-based therapies, and the perspectives of the EASD-ADA guidelines and when it is clinically appropriate to start prescribing incretins for blood glucose control.

This podcast is provided by EMJ and was supported by independent funding from Eli Lilly and Company, who did not influence the content of it. This educational activity is intended for an audience of non-US healthcare professionals.

 

Prof Michael Nauck

Head of Clinical Research at the Diabetes Division Medical Department of St. Josef-Hospital, Ruhr-University in Bochum, Germany.

Professor Nauck’s research interests include the pivotal role of gastrointestinal peptide hormones, including incretins, in both the physiological and therapeutic regulation of metabolism, as well as in the pathophysiology of type 2 diabetes. His groundbreaking contributions have been significant in shaping the treatment landscape of type 2 diabetes. He has played a pivotal role in developing novel therapeutic agents based on anti-diabetic properties of the gut hormone including GLP-1 (or Glucagon-like peptide-1).

His extensive scholarly output is underscored by numerous publications, and his outstanding scientific contributions have been honoured with several awards and accolades, including the Paul Langerhans Medal (2012) bestowed by the German Diabetes Association, and the Claude Bernard Medal from the European Association for the Study of Diabetes in 2022.

 

Dr. Priya Manjoo

Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia in Canada. 

Dr Manjoo is a diplomat of the American Board of Obesity Medicine and a Certified Specialist in Hypertension Medicine. She is also the director of the CardioMetabolic Collaborative Clinic located in Victoria, British Columbia, Canada and a member of the Victoria Lipid Clinic. She is a co-author of the Pharmacotherapy Section of the 2020 Canadian Adult Obesity Clinical Practice guidelines, as well as the 2022 chapter update and is an author of the 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia in Adults. Dr. Manjoo is a key opinion leader in the realms of diabetes, dyslipidaemia, and obesity management. Her invaluable contributions significantly contribute to advancing our understanding of these critical medical concepts.